US Patent

US11628162 — Methods of treating cancer with an FGFR inhibitor

Method of Use · Assigned to Incyte Corp · Expires 2040-08-30 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating cancer in a patient by administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor.

USPTO Abstract

This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.

Drugs covered by this patent

Pemazyre (PEMIGATINIB) · Incyte Corp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3568`	—	Pemazyre
`U-3569`	—	Pemazyre
`U-3568`	—	Pemazyre

Patent Metadata

Patent number: US11628162
Jurisdiction: US
Classification: Method of Use
Expires: 2040-08-30
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.